Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Mission Therapeutics
Mission Therapeutics
Activities:
Manufacturing
Drug Delivery
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
Mission Therapeutics announces FDA approval for Phase II trial in acute kidney injury
Mission gains clearance from US FDA for Phase II trial of MTX562 after it receives official approval of its Investigational New Drug (IND) application
Research & Development
Mission paper outlines potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson’s
The research was the result of collaborative work between Cambridge University, Harvard Medical School and Mission Therapeutics
Finance
Mission appoints Dr Suhail Nurbhai CMO
Dr Nurbhai has more than 25 years of experience in the strategic and operational leadership of all phases of clinical research and development at companies across Europe and the US
Ingredients
Mission raises $15m and expands relationship with Pfizer
The new capital will support the development of Mission's deubiquitylating enzymes (DUB) platform, as well as growth of its pipeline of DUB inhibitor programmes
Drug Delivery
Dr Nick Edmunds appointed to VP, Head of DUB Discovery
Recruitment
Mission Therapeutics strengthens clinical development team
Recruitment
Mission Therapeutics appoints Dr Bobby Soni to board
Subscribe now